Lesson plan

FP-LAD

FP-LAD, also known as fluoro-PRO-LAD, PROF-LAD, or TRALA-16, is a serotonin receptor modulator of the lysergamide family related to lysergic acid diethylamide (LSD; METH-LAD). It is specifically a fluorinated derivative of PRO-LAD (6-propyl-6-nor-LSD) and an analogue of FLUORETH-LAD (FE-LAD; 6-ethyl-6-nor-LSD). The drug has been reported to act as a potent ligand of the serotonin 5-HT 2 receptors. It had affinities (K i ) of 0.93 nM at the serotonin 5-HT 2A receptor, 1.8 nM at the serotonin 5-HT 2B receptor, and 3.7 nM at the serotonin 5-HT 2C receptor. FP-LAD was assessed and found to be a full agonist of the serotonin 5-HT 2A and 5-HT 2C receptors, with and values of 0.48 nM (93%) and 1.7 nM (97%), respectively. It had several-fold greater activational potency than LSD at the serotonin 5-HT 2A and 5-HT 2C receptors. The chemical synthesis of FP-LAD has been described. FP-LAD was patented by Daniel Trachsel and Matthias Liechti and colleagues in association with MindMed (Mind Medicine) in 2023. It had also previously been described in an earlier patent by Andrew Kruegel in association with Gilgamesh Pharmaceuticals in 2022. Hamilton Morris has described synthesizing FP-LAD and/or 1P-FP-LAD (1P-PROF-LAD or 1P-PROFLAD) with Lizard Labs in 2025. According to Morris, FP-LAD was active but had only about one-fifth of the potency of LSD.

Back to article

Article summary

FP-LAD, also known as fluoro-PRO-LAD, PROF-LAD, or TRALA-16, is a serotonin receptor modulator of the lysergamide family related to lysergic acid diethylamide (LSD; METH-LAD). It is specifically a fluorinated derivative of PRO-LAD (6-propyl-6-nor-LSD) and an analogue of FLUORETH-LAD (FE-LAD; 6-ethyl-6-nor-LSD). The drug has been reported to act as a potent ligand of the serotonin 5-HT 2 receptors. It had affinities (K i ) of 0.93 nM at the serotonin 5-HT 2A receptor, 1.8 nM at the serotonin 5-HT 2B receptor, and 3.7 nM at the serotonin 5-HT 2C receptor. FP-LAD was assessed and found to be a full agonist of the serotonin 5-HT 2A and 5-HT 2C receptors, with and values of 0.48 nM (93%) and 1.7 nM (97%), respectively. It had several-fold greater activational potency than LSD at the serotonin 5-HT 2A and 5-HT 2C receptors. The chemical synthesis of FP-LAD has been described. FP-LAD was patented by Daniel Trachsel and Matthias Liechti and colleagues in association with MindMed (Mind Medicine) in 2023. It had also previously been described in an earlier patent by Andrew Kruegel in association with Gilgamesh Pharmaceuticals in 2022. Hamilton Morris has described synthesizing FP-LAD and/or 1P-FP-LAD (1P-PROF-LAD or 1P-PROFLAD) with Lizard Labs in 2025. According to Morris, FP-LAD was active but had only about one-fifth of the potency of LSD.

Key claims

No claims recorded.

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  3. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

No sources recorded.

Key claims and bibliography are generated from the same tracked claims and sources as the article page.